https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e17515)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-01 / J Clin Oncol 36, 2018 (suppl; abstr e17515)2018-06-01 00:00:002018-06-01 00:00:00Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-01 / Open Med (Wars) 2018;13:83-89
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-01 / Open Med (Wars) 2018;13:83-892018-06-01 00:00:002018-06-01 00:00:00The Efficacy of Radiofrequency Hyperthermia Combined with Chemotherapy in the Treatment of Advanced Ovarian Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-11 / Sci Transl Med 2018 Apr;10(436)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-11 / Sci Transl Med 2018 Apr;10(436)2018-04-11 00:00:002019-02-15 08:52:24Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-20 / Biochem. Biophys. Res. Commun. 2017 12;494(1-2):13-19
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-20 / Biochem. Biophys. Res. Commun. 2017 12;494(1-2):13-192017-10-20 00:00:002019-02-15 08:52:23MtHsp70-CLIC1-pulsed dendritic cells enhance the immune response against ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-07-27 / J. Virol. 2017 08;91(16)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-07-27 / J. Virol. 2017 08;91(16)2017-07-27 00:00:002017-07-27 00:00:00Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells : Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-06 / Clin Transl Oncol 2017 Dec;19(12):1489-1497
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-06 / Clin Transl Oncol 2017 Dec;19(12):1489-14972017-06-06 00:00:002017-06-06 00:00:00Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-03 / Biomedicines 2016 May;4(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-03 / Biomedicines 2016 May;4(2)2016-05-03 00:00:002016-05-03 00:00:00Cancer Vaccines in Ovarian Cancer: How Can We Improve?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-29 / J Clin Oncol 33, 2015 (suppl; abstr e14033)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-29 / J Clin Oncol 33, 2015 (suppl; abstr e14033)2015-05-29 00:00:002015-05-29 00:00:00A study of mature alpha-DC-1 vaccine to induce immune responses in ovarian cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-02-26 / Gynecol. Oncol. 2015 May;137(2):335-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-02-26 / Gynecol. Oncol. 2015 May;137(2):335-422015-02-26 00:00:002019-02-15 08:52:21Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-10-01 / Gan To Kagaku Ryoho 2014 Oct;41(10):1295-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-10-01 / Gan To Kagaku Ryoho 2014 Oct;41(10):1295-72014-10-01 00:00:002014-10-01 00:00:00[The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer – 229 clinical cases]
